Want to see EMMA full AI Analyst Report?
EMMA Stock Chart & Stats
$0.01
<$0.01(8.70%)
At close: 4:00 PM EDT
$0.01
<$0.01(8.70%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.09
Previous CloseN/A
Volume100.00
Average Volume (3M)233.18K
Market Cap
$4.22M
Enterprise Value$28.94
Total Cash (Recent Filing)$2.81M
Total Debt (Recent Filing)$30.52M
Price to Earnings (P/E)―
Beta55.25
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding70,188,260
10 Day Avg. Volume248,130
30 Day Avg. Volume233,177
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.01
Price to Sales (P/S)0.07
P/FCF Ratio-69.38
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthStrong recent top-line growth indicates expanding demand for Endari and improved commercial traction in the sickle cell market. If maintained, this growth can support greater operating leverage, broaden the company’s revenue base, and improve its ability to fund ongoing operations.
High Gross MarginsConsistently very high gross margins provide substantial contribution from each product sale and suggest favorable pricing or product economics. This creates a foundation for future profitability if revenue scales and operating costs become better matched to the company’s commercial base.
Improved Cash GenerationThe shift to positive operating and free cash flow is an important improvement in financial self-sufficiency. Sustained cash generation would reduce reliance on external funding, support commercialization, and provide greater flexibility despite the company’s historically uneven cash-flow record.
Bears Say
Negative Equity And DebtPersistently negative equity leaves the company with a thin financial cushion and materially limits balance-sheet flexibility. Combined with meaningful debt, this increases refinancing and dilution risk and could constrain investment in commercialization or other strategic priorities.
Persistent UnprofitabilityOngoing net losses show that strong gross economics have not yet translated into sustainable bottom-line earnings. Continued deficits can consume financial resources, increase dependence on financing, and delay the point at which revenue growth becomes durable shareholder value creation.
Narrow Product ConcentrationDependence on a single marketed therapy concentrates commercial execution and revenue risk in Endari. Prescription volume, net pricing, reimbursement, and formulary access therefore have an outsized effect on the business, while limited product diversification reduces resilience if demand or coverage weakens.
Emmaus Life Sciences News
EMMA FAQ
What was Emmaus Life Sciences Inc’s price range in the past 12 months?
Emmaus Life Sciences Inc lowest stock price was <$0.01 and its highest was $0.09 in the past 12 months.
What is Emmaus Life Sciences Inc’s market cap?
Emmaus Life Sciences Inc’s market cap is $4.22M.
When is Emmaus Life Sciences Inc’s upcoming earnings report date?
Emmaus Life Sciences Inc’s upcoming earnings report date is Nov 18, 2026 which is in 71 days.
How were Emmaus Life Sciences Inc’s earnings last quarter?
Emmaus Life Sciences Inc released its earnings results on Aug 14, 2026. The company reported $0.011 earnings per share for the quarter.
Is Emmaus Life Sciences Inc overvalued?
According to Wall Street analysts Emmaus Life Sciences Inc’s price is currently Overvalued.
Does Emmaus Life Sciences Inc pay dividends?
Emmaus Life Sciences Inc does not currently pay dividends.
What is Emmaus Life Sciences Inc’s EPS estimate?
Emmaus Life Sciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Emmaus Life Sciences Inc have?
Emmaus Life Sciences Inc has 70,188,260 shares outstanding.
What happened to Emmaus Life Sciences Inc’s price movement after its last earnings report?
Emmaus Life Sciences Inc reported an EPS of $0.011 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Emmaus Life Sciences Inc?
Currently, no hedge funds are holding shares in EMMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Emmaus Life Sciences Inc
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical enterprise dedicated to the discovery, development, commercialization, and sale of treatments and therapies, primarily addressing rare and orphan diseases across the United States and internationally. The company's flagship product is Endari, an L-glutamine oral powder designed to mitigate the acute complications associated with sickle cell disease in patients aged five and above, covering both pediatric and adult populations. Furthermore, Emmaus maintains a collaborative arrangement with Kainos Medicine, Inc. for the preclinical advancement of Kainos' proprietary IRAK4 inhibitor, KM10544, which is being explored as a potential anti-cancer therapeutic. Established in 2000 as Emmaus Holdings, Inc., the organization rebranded to Emmaus Life Sciences, Inc. in September 2011 and operates from its headquarters in Torrance, California.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
CDT Equity
―